Preview: Diabetes and Liver Disease

In this video, Wendy Wright, DNP, ANP-BC, FNP-BC, provides an overview of the session "Diabetes and Liver Disease: Exploring the Intersections and Best Practices," at our Practical Updates in Primary Care 2023 Virtual Series, including identifying the difference between non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), and non-alcoholic steatohepatitis (NASH) in a primary care setting, the latest in the American Association of Clinical Endocrinologists guidelines, the diagnostic tools available to make a diagnosis, and the new and emerging therapies for the management of patients with diabetes. 

For more meeting coverage, visit the Practical Updates in Primary Care newsroom.

For more information about PUPC 2023 Virtual Series and to register for upcoming sessions, visit https://www.practicalupdates.consultant360.com/. 

Wendy Wright, DNP, ANP-BC, FNP-BC, is is an adult & family nurse practitioner and owner of Wright & Associates Family Healthcare (Amherst, NH). 

TRANSCRIPTION:

Dr Wendy Wright: I am Dr Wendy Wright, an adult and family nurse practitioner, and the owner of Wright & Associates Family Healthcare, a primary care clinic located in Amherst, New Hampshire. We are owned and operated by nurse practitioners and take care of approximately 6,000 primary care patients.

I want to invite you to join myself, and Dr. Peter Buck, and Carol Wysham as we discuss diabetes and liver disease, exploring the intersections and best practices.

We're going to be covering the difference between non-alcoholic fatty liver disease, non-alcoholic fatty liver, and non-alcoholic steatohepatitis. And I think in primary care there's often a difficulty with trying to differentiate between those. We're going to talk about those risk factors that set our patients up for non-alcoholic fatty liver, and we'll talk about the latest in the AACE guidelines and the recommended diagnostic tools to make this diagnosis. And last, we're going to assess the impact of new and emerging therapies for diabetes and fatty liver disease that may have an impact on patient outcomes, and we'll incorporate them into clinical practice as appropriate.

So, I hope you will join us as we discuss non-alcoholic fatty liver, which is actually the most common liver disease in the world. In fact, in primary care, it's estimated that about 25 to 30% of all of our patients are affected by this condition, yet so often patients go undiagnosed or maybe even misdiagnosed. So, myself and my colleagues are going to discuss how can you in primary care make these diagnoses. How can we do it accurately? And we're going to talk about what are the latest recommendations to help us to identify those patients who already have fibrosis or who are very likely to progress on, and most importantly, join us as we discuss what can you do when you've made that diagnosis in terms of what diets are best, what can people do with their lifestyle, and what medications are available to change the trajectory of what could be a very harmful disease for our patients.

Thank you so much and I look forward to you joining us.